Pink’s reopens after voluntary closure for COVID
Pink’s Hot Dogs, a Los Angeles culinary institution since 1939, reopened March 1 after a nearly two-month COVID-related closure. The hot dog stand voluntarily shut down in early January amid a citywide coronavirus spike.
SUBSCRIBE FOR MORE VIDEOS AND NEWS
http://www.youtube.com/subscription_center?add_user=losangelestimes
https://www.latimes.com/subscription
LET’S CONNECT:
Facebook ► https://www.facebook.com/latimes
Twitter ► https://twitter.com/LATimes
Instagram ► https://www.instagram.com/latimes
March 01, 2021
IQD05TcraGw
Newsom and legislators strike deal to offer schools $2 billion in incentives to reopen campuses soon
Gov. Gavin Newsom and Democratic legislative leaders announced an agreement Monday to give school districts $2 billion to open schools for students in transitional kindergarten through second grade by April 1.
SUBSCRIBE FOR MORE VIDEOS AND NEWS
http://www.youtube.com/subscription_center?add_user=losangelestimes
https://www.latimes.com/subscription
LET’S CONNECT:
Facebook ► https://www.facebook.com/latimes
Twitter ► https://twitter.com/LATimes
Instagram ► https://www.instagram.com/latimes
March 01, 2021
OCCyFOduCZg
“Cherry” directors on their career and influences
Anthony Russo and Joe Russo, directors of the film “Cherry,” discuss their start in the industry and their enduring love of French New Wave director François Truffaut.
Screening and Q&A are sponsored by Apple TV+. Sponsor has no influence over the content of the post-screening discussion.
SUBSCRIBE FOR MORE VIDEOS AND NEWS
http://www.youtube.com/subscription_center?add_user=losangelestimes
https://www.latimes.com/subscription
LET’S CONNECT:
Facebook ► https://www.facebook.com/latimes
Twitter ► https://twitter.com/LATimes
Instagram ► https://www.instagram.com/latimes
February 26, 2021
SrkEBwB6cAU
Envelope Live Full Q+A: CHERRY, sponsored by Apple TV+
Tune in for a Q+A with Anthony Russo, co-director of CHERRY, along with co-director Joe Russo, writer Jessica Goldberg and writer Angela Russo Otstot in conversation with L.A. Times staff writer Michael Ordoña.
Screening and Q&A are sponsored by Apple TV+. Sponsor has no influence over the content of the post-screening discussion.
SUBSCRIBE FOR MORE VIDEOS AND NEWS
http://www.youtube.com/subscription_center?add_user=losangelestimes
https://www.latimes.com/subscription
LET’S CONNECT:
Facebook ► https://www.facebook.com/latimes
Twitter ► https://twitter.com/LATimes
Instagram ► https://www.instagram.com/latimes
February 26, 2021
YewB4v0P9pg
“Cherry” screenwriters on finding the “hook”
Jessica Goldberg and Angela Russo-Otstot, screenwriters of “Cherry,” discuss how they went about adapting the novel of the same name, and their decision to focus on the love story running throughout the book.
Screening and Q&A are sponsored by Apple TV+. Sponsor has no influence over the content of the post-screening discussion.
SUBSCRIBE FOR MORE VIDEOS AND NEWS
http://www.youtube.com/subscription_center?add_user=losangelestimes
https://www.latimes.com/subscription
LET’S CONNECT:
Facebook ► https://www.facebook.com/latimes
Twitter ► https://twitter.com/LATimes
Instagram ► https://www.instagram.com/latimes
February 26, 2021
YMvhBhpkH0s
“Cherry” co-director on placing the movie “within the character’s subjective experience”
Anthony Russo, co-director of “Cherry,” discusses the different cinematic techniques he used during production to get inside the mind of the protagonist.
Screening and Q&A are sponsored by Apple TV+. Sponsor has no influence over the content of the post-screening discussion.
SUBSCRIBE FOR MORE VIDEOS AND NEWS
http://www.youtube.com/subscription_center?add_user=losangelestimes
https://www.latimes.com/subscription
LET’S CONNECT:
Facebook ► https://www.facebook.com/latimes
Twitter ► https://twitter.com/LATimes
Instagram ► https://www.instagram.com/latimes
February 26, 2021
BGiFPilbDgI
Black journalists talk about covering racism and the pandemic
Join five Black journalists in a conversation about working on the frontlines, covering what many have called the dual pandemic of COVID-19 and systemic racism.
Tune in on Feb. 25 at 6 p.m. Pacific. Times Assistant Managing Editor Angel Jennings will host a discussion with Tyrone Beason, Makeda Easter, LZ Granderson and Erika D. Smith about the pressures of being Black while documenting this moment in history.
Ask A Reporter is the live meetup series where L.A Times reporters and editors discuss the news and answer your questions about current issues.
February 25, 2021
uSSXi5eKx9I
Novelist Charlotte McConaghy live from Australia
Charlotte McConaghy, author of the eco-novel ‘Migrations,” will be in conversation with Times reporter Rosanna Xia.
Tune in on Feb. 24 at 7 p.m. Pacific when McConaghy joins the L.A. Times Book Club from Sydney to discuss her U.S. breakthrough and the challenges of writing about climate change and the natural world.
February 24, 2021
V2PFirCMsN0
Massive proposed dam project could displace thousands in Lebanon
Bisri Valley is the proposed site of Lebanon’s second-largest dam, a mega-project aimed to serve Beirut’s growing population. The dam would submerge agricultural fields, forests and wild lands, displacing thousands of farmers and workers in adjacent villages. Environmental activists have waged an escalating campaign against the Bisri dam.
February 19, 2021
A1mWAqLDe8A
Watch NASA’s Perseverance rover make a safe landing on Mars
NASA’s Perseverance rover touched down safely on the surface of Mars on Thursday, completing a 293-million-mile journey through space. The mission seeks to find evidence of ancient extraterrestrial life.
February 18, 2021
WBvGMhtBAPc
Influential conservative radio host Rush Limbaugh dies of lung cancer
Rush Limbaugh, the controversial and widely influential conservative radio personality, author and former television host, has died, his wife confirmed Wednesday. During his career, Limbaugh amassed tens of millions of listeners and was, at his peak, the most-listened-to radio show host in the nation.
SUBSCRIBE FOR MORE VIDEOS AND NEWS
http://www.youtube.com/subscription_center?add_user=losangelestimes
https://www.latimes.com/subscription
LET’S CONNECT:
Facebook ► https://www.facebook.com/latimes
Twitter ► https://twitter.com/LATimes
Instagram ► https://www.instagram.com/latimes
February 17, 2021
tlFKoeX1mO8
From L.A. Times Studios: Four questions and answers about the California variant
A new strain of the coronavirus recently surfaced in Southern California, concerning public health officials as it spreads worldwide. Los Angeles Times executive chairman Dr. Patrick Soon-Shiong answers four key questions about the California variant in this video produced by L.A. Times Studios.
Patrick Soon-Shiong is a surgeon and scientist who has spent his career studying the human immune system to fight cancer and infectious disease. Last year, Soon-Shiong's company, ImmunityBio, received permission from the Food and Drug Administration to begin Phase 1 trials of its COVID-19 vaccine candidate. He has also received approval to begin trials in South Africa, where he will explore the potential of his T cell vaccine to prevent infection from mutated virus strains of the coronavirus.
SUBSCRIBE FOR MORE VIDEOS AND NEWS
http://www.youtube.com/subscription_center?add_user=losangelestimes
https://www.latimes.com/subscription
LET’S CONNECT:
Facebook ► https://www.facebook.com/latimes
Twitter ► https://twitter.com/LATimes
Instagram ► https://www.instagram.com/latimes
February 16, 2021
hKro3YQAd20
Gov. Gavin Newsom on the vaccine: 'Do the math. Supply is the issue.'
Speaking at a new vaccine center at Cal State Los Angeles, Gov. Gavin Newsom laid out plans to expand the state’s capacity to administer more vaccines despite the current lag in supply.
SUBSCRIBE FOR MORE VIDEOS AND NEWS
http://www.youtube.com/subscription_center?add_user=losangelestimes
https://www.latimes.com/subscription
LET’S CONNECT:
Facebook ► https://www.facebook.com/latimes
Twitter ► https://twitter.com/LATimes
Instagram ► https://www.instagram.com/latimes
February 16, 2021
GZEWI8KRf4U
From L.A. Times Studios: A look at the Science Behind the Coronavirus, Series IV
In this excerpt from the L.A. Times Studios production "The Science Behind the Coronavirus series IV," Los Angeles Times executive chairman Dr. Patrick Soon-Shiong discusses the threat that "vaccine nationalism" poses to low- and middle-income countries. Dr. Soon-Shiong's guest is the Johannesburg-based virologist Shabir Madhi, who managed South Africa's trials of the AstraZeneca-Oxford vaccine.
You can watch the full "Science Behind the Coronavirus" series at www.latimes.com/secondopinion.
Patrick Soon-Shiong is a surgeon and scientist who has spent his career studying the human immune system to fight cancer and infectious disease. Last year, Soon-Shiong's company, ImmunityBio, received permission from the Food and Drug Administration to begin Phase 1 trials of its COVID-19 vaccine candidate. The company has also received approval to begin trials in South Africa, where a new variant of the virus has led to a sudden rise in cases.
SUBSCRIBE FOR MORE VIDEOS AND NEWS
http://www.youtube.com/subscription_center?add_user=losangelestimes
https://www.latimes.com/subscription
LET’S CONNECT:
Facebook ► https://www.facebook.com/latimes
Twitter ► https://twitter.com/LATimes
Instagram ► https://www.instagram.com/latimes
February 16, 2021
x_qXtk7bp-k
Trump acquitted in second impeachment trial
The Senate voted Saturday to acquit former President Trump of inciting the insurrection at the U.S. Capitol last month, marking the end of his second impeachment trial.
Seven Republican senators broke ranks to support conviction. The 57-43 vote fell far short of the 67 votes needed for conviction, but it was the most bipartisan guilty vote in a presidential impeachment trial and exposed the fractures in a Republican Party divided over its future.
The Republicans who voted for conviction were Sens. Richard Burr of North Carolina, Bill Cassidy of Louisiana, Susan Collins of Maine, Lisa Murkowski of Alaska, Mitt Romney of Utah, Ben Sasse of Nebraska and Pat Toomey of Pennsylvania.
Trump is the first president to be impeached twice and his trial was the first in American history of a former president.
SUBSCRIBE FOR MORE VIDEOS AND NEWS
http://www.youtube.com/subscription_center?add_user=losangelestimes
https://www.latimes.com/subscription
LET’S CONNECT:
Facebook ► https://www.facebook.com/latimes
Twitter ► https://twitter.com/LATimes
Instagram ► https://www.instagram.com/latimes
February 13, 2021
9lc6Sl1WwXY
The Science Behind the Coronavirus, Series IV: Variants and Vaccines
In the fourth installment of the Los Angeles Times series “The Science Behind Coronavirus,” Dr. Patrick Soon-Shiong, the executive chairman of the Los Angeles Times, discusses South Africa’s recent decision to halt the rollout of the AstraZeneca-Oxford coronavirus vaccine — and what it means for efforts to contain new strains of the virus.
Dr. Soon-Shiong’s guest is Shabir Madhi, lead investigator in South Africa’s clinical trials of the AstraZeneca-Oxford vaccine. Madhi’s research found that the vaccine, promising against the earlier form of the virus, did not prevent mild to moderate cases of the variant now dominant in that country. The million doses of the vaccine were going to be administered to South African healthcare workers as the first phase of a broad vaccination plan. The pause comes as the country battles a new, highly contagious strain of the virus. South Africa has seen nearly 1.5 million cases of the virus as of mid-February, and more than 47,000 people in that country have died.
Professor Shabir Madhi is the dean of faculty of health sciences at the University of the Witwatersrand, Johannesburg, and director of the university’s Vaccines and Infectious Diseases Analytics Research Unit. He is also co-director of the African Local Initiative for Vaccinology Expertise, a program dedicated to increasing vaccine research activity in Africa.
Dr. Patrick Soon-Shiong is a surgeon and scientist who has spent his career studying the human immune system to fight cancer and infectious disease. Last year, Soon-Shiong's company, ImmunityBio, received permission from the Food and Drug Administration to begin Phase 1 trials of its COVID-19 vaccine candidate. He has also received approval to begin trials in South Africa, where he will explore the potential of his T cell vaccine to prevent infection from mutated virus strains of the coronavirus.
SUBSCRIBE FOR MORE VIDEOS AND NEWS
http://www.youtube.com/subscription_center?add_user=losangelestimes
https://www.latimes.com/subscription
LET’S CONNECT:
Facebook ► https://www.facebook.com/latimes
Twitter ► https://twitter.com/LATimes
Instagram ► https://www.instagram.com/latimes
February 12, 2021
081-YJLN28o
Chapter 3: Vaccine nationalism
“Vaccine nationalism” is the final topic of Dr. Patrick Soon-Shiong’s discussion with Shabir Madhi, a Johannesburg-based virologist who led South Africa’s trials of the AstraZeneca-Oxford coronavirus vaccine.
Madhi’s team of investigators found that the vaccine did not protect against mild to moderate cases of the variant now predominant in South Africa, leading the government to announce that it would stop distribution of the vaccine. The news was a setback for the country, where more than 47,000 people have died of COVID-19 as of mid-February, and a new variant is driving a surge of cases.
South Africa acquired the doses from a manufacturer based in India, at prices exceeding what other African countries and countries in Europe have arranged. South Africa’s president, Cyril Ramaphosa, has also complained that wealthier countries are holding onto stockpiles of the vaccine while his country pursues a patchwork of deals with manufacturers and relies on COVAX, a group distributing vaccines to low- and middle-income countries. Ramaphosa has called for collaboration between countries and an end to what he and others refer to as “vaccine nationalism.”
Professor Shabir Madhi is the dean of faculty of health sciences at the University of the Witwatersrand, Johannesburg, and director of the university’s Vaccines and Infectious Diseases Analytics Research Unit. He is also co-director of the African Local Initiative for Vaccinology Expertise, a program dedicated to increasing vaccine research activity in Africa.
Dr. Patrick Soon-Shiong is a surgeon and scientist who has spent his career studying the human immune system to fight cancer and infectious disease. Last year, Soon-Shiong's company, ImmunityBio, received permission from the Food and Drug Administration to begin Phase 1 trials of its COVID-19 vaccine candidate. The company has also received approval to begin trials in South Africa, where a new variant of the virus has led to a sudden rise in cases.
SUBSCRIBE FOR MORE VIDEOS AND NEWS
http://www.youtube.com/subscription_center?add_user=losangelestimes
https://www.latimes.com/subscription
LET’S CONNECT:
Facebook ► https://www.facebook.com/latimes
Twitter ► https://twitter.com/LATimes
Instagram ► https://www.instagram.com/latimes
February 12, 2021
tfXHQK0Ajrc
Chapter 2: The next generation of COVID-19 vaccines
Shabir Madhi, a virologist who led South Africa’s trials of the AstraZeneca-Oxford vaccine, discusses the scientific community’s effort to combat the coronavirus. The challenge has only become more difficult in recent months as mutations of the virus have shown resistance to antibodies derived from past coronavirus infections or vaccines.
Madhi’s research is among the latest signs that mutated strains of the virus present a new threat to public health. The South African government announced that it would halt distribution of the AstraZeneca-Oxford vaccine after Madhi’s team of investigators found the vaccine did not protect against mild or moderate cases of the variant driving a surge of cases in that country.
Professor Shabir Madhi is the dean of faculty of health sciences at the University of the Witwatersrand, Johannesburg, and director of the university’s Vaccines and Infectious Diseases Analytics Research Unit. He is also co-director of the African Local Initiative for Vaccinology Expertise, a program dedicated to increasing vaccine research activity in Africa.
Dr. Patrick Soon-Shiong is host of “The Science Behind the Coronavirus.” Soon-Shiong is a surgeon and scientist who has spent his career studying the human immune system to fight cancer and infectious disease. Last year, Soon-Shiong's company, ImmunityBio, received permission from the Food and Drug Administration to begin Phase 1 trials of its COVID-19 vaccine candidate. The company has also received approval to begin trials in South Africa, where a new variant of the virus has led to a sudden rise in cases.
SUBSCRIBE FOR MORE VIDEOS AND NEWS
http://www.youtube.com/subscription_center?add_user=losangelestimes
https://www.latimes.com/subscription
LET’S CONNECT:
Facebook ► https://www.facebook.com/latimes
Twitter ► https://twitter.com/LATimes
Instagram ► https://www.instagram.com/latimes
February 12, 2021
QUnuV8-rrGI
Chapter 1: Vaccine trials in South Africa
Shabir Madhi, a virologist and lead investigator in South Africa’s clinical trials of the AstraZeneca-Oxford coronavirus vaccine, discusses his research. The South African government announced it would halt distribution of that vaccine after Madhi’s team of scientists found that it did not protect against mild or moderate forms of the coronavirus variant now dominant in that country.
During a press briefing, South African officials said further research would need to show that the vaccine protects against severe disease. In a statement, the drugmaker pointed out that the trials were limited to a small and predominantly healthy group of adults. “We believe our vaccine will protect against severe disease caused by the new B.1.351 variant,” AstraZeneca said, referring to the strain driving a surge of cases in South Africa.
Madhi said the results of his study, while disappointing, are a reminder that the “game is far from over” on vaccine development. “What it tells us is that to be able to protect against infection probably is a much higher bar than what is required of a vaccine to be able to protect against severe disease,” he said.
Professor Shabir Madhi is the dean of faculty of health sciences at the University of the Witwatersrand, Johannesburg, and director of the university’s Vaccines and Infectious Diseases Analytics Research Unit. He is also co-director of the African Local Initiative for Vaccinology Expertise, a program dedicated to increasing vaccine research activity in Africa.
Dr. Patrick Soon-Shiong is host of “The Science Behind the Coronavirus.” Soon-Shiong is a surgeon and scientist who has spent his career studying the human immune system to fight cancer and infectious disease. Last year, Soon-Shiong's company, ImmunityBio, received permission from the Food and Drug Administration to begin Phase 1 trials of its COVID-19 vaccine candidate. The company has also received approval to begin trials in South Africa, where a new variant of the virus has led to a sudden rise in cases.
SUBSCRIBE FOR MORE VIDEOS AND NEWS
http://www.youtube.com/subscription_center?add_user=losangelestimes
https://www.latimes.com/subscription
LET’S CONNECT:
Facebook ► https://www.facebook.com/latimes
Twitter ► https://twitter.com/LATimes
Instagram ► https://www.instagram.com/latimes
February 12, 2021
p64MMJIVxy0
Trevor Bauer officially signs with the Dodgers
Pitcher Trevor Bauer official became a member of the Los Angeles Dodgers and discussed why he signed with the team.
SUBSCRIBE FOR MORE VIDEOS AND NEWS
http://www.youtube.com/subscription_center?add_user=losangelestimes
https://www.latimes.com/subscription
LET’S CONNECT:
Facebook ► https://www.facebook.com/latimes
Twitter ► https://twitter.com/LATimes
Instagram ► https://www.instagram.com/latimes
February 11, 2021
2JkzojvaRYU